IL13RA2 and breast carcinoma: Kawakami et al. [27], who observed growth inhibition by IL13RA2 overexpression in a breast cancer model, noted that IL13RA2 levels decrease over time in vivo, suggesting that IL13RA2 deficiency is beneficial during the later stages of tumor growth.